Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 2, 2015, Pages E156-E165

  Maldonado, Roberto A ^a   LaMothe, Robert A ^a   Ferrari, Joseph D ^a   Zhang, Ai Hong ^b   Rossi, Robert J ^b   Kolte, Pallavi N ^a   Griset, Aaron P ^a   O'Neil, Conlin ^a   Altreuter, David H ^a   Browning, Erica ^a   Johnston, Lloyd ^a   Farokhzad, Omid C ^c,d   Langer, Robert ^e,f   Scott, David W ^b   Von Andrian, Ulrich H ^g,h   Kishimoto, Takashi Kei ^a  

^a Selecta Biosciences Inc   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^e Massachusetts Institute of Technology Cambridge   (United States)

^f David H Koch Institute for Integrative Cancer Research   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anti drug antibodies; Immune tolerance; Immunotherapy; Nanoparticles; Rapamycin

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; KEYHOLE LIMPET HEMOCYANIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NANOCARRIER; OVALBUMIN; POLYGLACTIN; PROTEOLIPID PROTEIN; RAPAMYCIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; RESIQUIMOD; TOLEROGENIC NANOPARTICLE; UNCLASSIFIED DRUG; ANTIGEN; BLOOD CLOTTING FACTOR 8; CPG-OLIGONUCLEOTIDE; HEMOCYANIN; IMMUNOSUPPRESSIVE AGENT; KEYHOLE-LIMPET HEMOCYANIN; LACTIC ACID; NANOCAPSULE; NANOPARTICLE; OLIGODEOXYRIBONUCLEOTIDE; OVALBUMIN (325-339); PEPTIDE; PEPTIDE FRAGMENT; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; PROTEIN; RECOMBINANT PROTEIN;

ALLERGIC AIRWAY INFLAMMATION; ALLERGIC ENCEPHALOMYELITIS; ALLERGIC REACTION; ANAPHYLAXIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FEMALE; HEMOPHILIA A; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IN VIVO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; MOUSE; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SENSITIZATION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DISEASE MODEL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HYPERSENSITIVITY, DELAYED; IMMUNOLOGY; PROCEDURES;

ANIMALIA; MUS;

ANIMALS; ANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FACTOR VIII; FEMALE; HEMOCYANIN; HEMOPHILIA A; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNE TOLERANCE; IMMUNITY, HUMORAL; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LACTIC ACID; MICE; MICE, INBRED BALB C; NANOCAPSULES; NANOPARTICLES; OLIGODEOXYRIBONUCLEOTIDES; OVALBUMIN; PEPTIDE FRAGMENTS; PEPTIDES; POLYGLYCOLIC ACID; PROTEINS; RECOMBINANT PROTEINS; SIROLIMUS;

EID: 84920935888     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1408686111     Document Type: Article

References (47)

1. Burks AW, et al. (2013) Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/ PRACTALL consensus report. J Allergy Clin Immunol 131(5):1288-1296, e1283.
2. Hayter SM, Cook MC (2012) Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev 11(10):754-765.
3. Nechansky A, Kircheis R (2010) Immunogenicity of therapeutics: A matter of efficacy and safety. Expert opin drug discov 5(11):1067-1079.
4. Zhang AH, Skupsky J, Scott DW (2009) Factor VIII inhibitors: Risk factors and methods for prevention and immune modulation. Clin Rev Allergy Immunol 37(2):114-124.
5. Banugaria SG, Patel TT, Kishnani PS (2012) Immune modulation in Pompe disease treated with enzyme replacement therapy. Expert Rev Clin Immunol 8(6):497-499.
6. Carbone J, del Pozo N, Gallego A, Sarmiento E (2011) Immunological risk factors for infection after immunosuppressive and biologic therapies. Expert Rev Anti Infect Ther 9(4):405-413.
7. Riminton DS, Hartung HP, Reddel SW (2011) Managing the risks of immunosuppression. Curr Opin Neurol 24(3):217-223.
8. Bluestone JA, Bour-Jordan H (2012) Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol 4(11):pii: a007542.
9. Smarr CB, Hsu CL, Byrne AJ, Miller SD, Bryce PJ (2011) Antigen-fixed leukocytes tolerize Th2 responses in mouse models of allergy. J Immunol 187(10):5090-5098.
10. Miller SD, Wetzig RP, Claman HN (1979) The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells. J Exp Med 149(3):758-773.
11. Scott DW, Long CA (1976) Role of self-carriers in the immune response and tolerance. I. B-cell unresponsiveness and cytotoxic T-cell immunity induced by haptenated syngeneic lymphoid cells. J Exp Med 144(5):1369-1374.
12. Battisto JR, Bloom BR (1966) Dual immunological unresponsiveness induced by cell membrane coupled hapten or antigen. Nature 212(5058):156-157.
13. Getts DR, et al. (2012) Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol 30(12):1217-1224.
14. Getts DR, et al. (2014) Therapeutic inflammatory monocyte modulation using immune-modifying microparticles. Sci Transl Med 6(219):219ra217.
15. Kontos S, Kourtis IC, Dane KY, Hubbell JA (2013) Engineering antigens for in situ erythrocyte binding induces T-cell deletion. Proc Natl Acad Sci USA 110(1):E60-E68.
16. Irvine DJ, Swartz MA, Szeto GL (2013) Engineering synthetic vaccines using cues from natural immunity. Nat Mater 12(11):978-990.
17. Tsai S, et al. (2010) Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 32(4):568-580.
18. Macauley MS, et al. (2013) Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis. J Clin Invest 123(7):3074-3083.
19. Yeste A, Nadeau M, Burns EJ, Weiner HL, Quintana FJ (2012) Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 109(28):11270-11275.
20. Joseph A, Munroe K, Housman M, Garman R, Richards S (2008) Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin Exp Immunol 152(1):138-146.
21. Steinman RM, Hawiger D, Nussenzweig MC (2003) Tolerogenic dendritic cells. Annu Rev Immunol 21:685-711.
22. Maldonado RA, von Andrian UH (2010) How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 108:111-165.
23. Thomson AW (2010) Tolerogenic dendritic cells: All present and correct? Am J Transplant 10(2):214-219.
24. Manicassamy S, Pulendran B (2011) Dendritic cell control of tolerogenic responses. Immunol Rev 241(1):206-227.
25. Cobbold SP, Adams E, Nolan KF, Regateiro FS, Waldmann H (2010) Connecting the mechanisms of T-cell regulation: Dendritic cells as the missing link. Immunol Rev 236:203-218.
26. Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW (2005) Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant 5(2):228-236.
27. Fischer R, Turnquist HR, Taner T, Thomson AW (2009) Use of rapamycin in the induction of tolerogenic dendritic cells. Handb Exp Pharmacol (188):215-232.
28. Powell JD, Pollizzi KN, Heikamp EB, Horton MR (2012) Regulation of immune responses by mTOR. Annu Rev Immunol 30:39-68.
29. Araki K, Ellebedy AH, Ahmed R (2011) TOR in the immune system. Curr Opin Cell Biol 23(6):707-715.
30. Bachmann MF, Jennings GT (2010) Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10(11):787-796.
31. Metcalfe SM, Fahmy TM (2012) Targeted nanotherapy for induction of therapeutic immune responses. Trends Mol Med 18(2):72-80.
32. Look M, et al. (2013) Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice. J Clin Invest 123(4):1741-1749.
33. Goodnow CC, et al. (1988) Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 334(6184):676-682.
34. Vasquez KO, Casavant C, Peterson JD (2011) Quantitative whole body biodistribution of fluorescent-labeled agents by non-invasive tomographic imaging. PLoS ONE 6(6):e20594.
35. Liu E, et al. (2002) Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. J Clin Invest 110(7):1021-1027.
36. Krieckaert C, Rispens T, Wolbink G (2012) Immunogenicity of biological therapeutics: From assay to patient. Curr Opin Rheumatol 24(3):306-311.
37. Vultaggio A, Maggi E, Matucci A (2011) Immediate adverse reactions to biologicals: From pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol 11(3):262-268.
38. Qian J, Borovok M, Bi L, Kazazian HH, Jr, Hoyer LW (1999) Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 81(2):240-244.
39. Selecta Biosciences (2011) Safety and Pharmacodynamics of SEL-068 Vaccine in Smokers and Non-Smokers. Available at www. ClinicalTrials. gov.
40. Araki K, et al. (2009) mTOR regulates memory CD8 T-cell differentiation. Nature 460(7251):108-112.
41. Smarr CB, Bryce PJ, Miller SD (2013) Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases. Crit Rev Immunol 33(5):389-414.
42. Scott DW, Pratt KP, Miao CH (2013) Progress toward inducing immunologic tolerance to factor VIII. Blood 121(22):4449-4456.
43. Enever C, Batuwangala T, Plummer C, Sepp A (2009) Next generation immunotherapeutics- Honing the magic bullet. Curr Opin Biotechnol 20(4):405-411.
44. Astete CE, Sabliov CM (2006) Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed 17(3):247-289.
45. Bi L, et al. (1995) Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 10(1):119-121.
46. Bailón E, et al. (2012) A shorter and more specific oral sensitization-based experimental model of food allergy in mice. J Immunol Methods 381(1-2):41-49.
47. Kasper CK, et al. (1975) Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34(2):612.